Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s R&D?
- Design Therapeutics, Inc. (DSGN) reported R&D of $14.38M in Q1 2026.
- How has Design Therapeutics, Inc.'s R&D changed year-over-year?
- Design Therapeutics, Inc.'s R&D decreased by 6.5% year-over-year, from $15.38M to $14.38M.
- What is the long-term trend for Design Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s R&D has grown at a 24.3% compound annual growth rate (CAGR), from $24.78M to $59.13M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Design Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude